We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.002 | -0.13% | 1.565 | 1.53 | 1.60 | 1.53 | 1.53 | 1.53 | 6,130,743 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.37 | 17.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/5/2024 15:46 | It don’t seem to be doing well today,much the same as most other days. | albert35911 | |
01/5/2024 03:33 | trade the spike to 3.5-4p on results xXTiPSXHEETSXx 5 month HOLD | purple11 | |
30/4/2024 11:39 | The speculation of prepping One patient for the clinical trial is pants The clinical trials will proceed with multiples of patients from all walks of life and Metabolisms The History of Car-t therapy has not been a 100% Success ! More positive outcomes from the younger Generation than Favoring The Older Generation ! although taking into consideration the Patients Prior lines of Treatment Will be Strictly monitored. ph1 formality of selected Patients Infusion and monitored over a period of time progressing t/ward P11 Pending Results ? | dreamtwister | |
29/4/2024 09:03 | O YES xXTiPSXHEETSXx see CR Thread | purple11 | |
29/4/2024 08:59 | Noted by Prevail in Sept RNS 👍 Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." | purple11 | |
28/4/2024 16:40 | just watched the pod cast, im not sure but it came a cross as Dr Sandler HOPED to have the first patient infused for the start of the clinical Trial. Well I Hope they have more than one patient ? What Happens if that patient has withdrawal symptoms from the car-t side effects ? nope the interview has not hit the buy button so many un answered questions. The one question that needs to be addressed That the Fda highlighted & the reason for the Clinical trials hold was the purity/contamination of the Lentivirus ? The lentivirus is manufactured by Wuxi pharma china so a 3/4 week delivery window for a fresh batch of the lentivirus maybe the reason for the radio silence from Hemogenyx was that they had to or was told to produce a further 3 identical production runs before the clinical hold was lifted ! "sorry no room for errors" I Hope hemogenyx has found a alternative supplier of the lentivirus. | dreamtwister | |
27/4/2024 15:47 | How are your 2.3p PPP shares doing purple11?...... LOL Simples!...... :-) | nigoil | |
26/4/2024 22:03 | Hemo interviewToday 16:45 | purple11 | |
26/4/2024 15:56 | firming up up 6% still alot of interest in this stock as we approach a massive inflexion point with the trials gl xXTiPSXHEETSXx see CR Thread | purple11 | |
26/4/2024 15:05 | 100% correct albert35911.... :-) purple11 is the biggest offender! Simples!...... :-) | nigoil | |
26/4/2024 13:34 | tillywhizz lse ulver - good post , Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price , I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail . Noted by Prevail in Sept RNS Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." Let’s see what next few months bring | purple11 | |
25/4/2024 16:25 | Nigoil…you have to laugh at their desperation. | albert35911 | |
25/4/2024 16:23 | How's your 2.3p PPP shares doing purple11?......LOL Don't follow purple11 advice, he was touting PPP as a bargain when they were 5p!........LOL Simples!.........;-) | nigoil | |
25/4/2024 16:09 | Hemo will be out of cash once again by the time the trial starts. | john henry | |
25/4/2024 15:50 | Another penny share that will bite the dust. | albert35911 | |
25/4/2024 15:28 | yeah,and so are phase 1 trials just around the corner positive news from that and were off to the races,theyll easilly be able to raise higher next time. | purple11 | |
25/4/2024 12:33 | theyve just done a large placing.plenty of money to last for the foreseeable. | purple11 | |
25/4/2024 08:36 | What is the CAB to 31/12/23 What is the remaining cash runway Anyone know? Looks like the burn is still £550k pcm | porky9 | |
25/4/2024 07:48 | Feel for long term holders. More money needed and no explanation as to where it's going to come from. A lot of talk of the past and very little on the future. | trying2trade | |
25/4/2024 07:42 | How are your 2.3p PPP shares doing purple11?....... LOL Simples!........ :-) | nigoil | |
25/4/2024 07:27 | Lots of admin expenses | countbasie1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions